In palliative care, what is the recommended pharmacologic approach to agitation in delirium, and what safety monitoring is advised?

Study for ELNEC 4: Symptom Management in Palliative Care Test with flashcards and multiple choice questions. Hints and explanations included! Get ready for your exam!

Multiple Choice

In palliative care, what is the recommended pharmacologic approach to agitation in delirium, and what safety monitoring is advised?

When delirium in palliative care presents with agitation, the aim is to calm the patient safely and promptly without adding burdens. A low-dose antipsychotic such as haloperidol or quetiapine is preferred because it effectively reduces agitation and psychomotor excitement with a manageable safety profile when used judiciously. Benzodiazepines, while sometimes helpful for certain contexts, can worsen delirium and respiratory status when used routinely, so they’re not the go-to first-line choice for general agitation in delirium. Using high doses of antipsychotics increases the risk of adverse effects—like extrapyramidal symptoms, sedation, hypotension, and cardiac rhythm problems—without guaranteeing quicker or safer control of symptoms. Antidepressants don’t address the acute agitation of delirium and aren’t appropriate for immediate management. Safety monitoring centers on the heart, since many antipsychotics can prolong the QT interval. Baseline ECG when feasible, with ongoing QTc monitoring during therapy, helps detect problematic changes early, especially if other QT-prolonging drugs or electrolyte disturbances are present. Regular checks for sedation level, movement disorders, and hydration/electrolyte status are also important, with dose adjustments or switching agents if adverse effects or significant QT prolongation occur.

When delirium in palliative care presents with agitation, the aim is to calm the patient safely and promptly without adding burdens. A low-dose antipsychotic such as haloperidol or quetiapine is preferred because it effectively reduces agitation and psychomotor excitement with a manageable safety profile when used judiciously. Benzodiazepines, while sometimes helpful for certain contexts, can worsen delirium and respiratory status when used routinely, so they’re not the go-to first-line choice for general agitation in delirium. Using high doses of antipsychotics increases the risk of adverse effects—like extrapyramidal symptoms, sedation, hypotension, and cardiac rhythm problems—without guaranteeing quicker or safer control of symptoms. Antidepressants don’t address the acute agitation of delirium and aren’t appropriate for immediate management.

Safety monitoring centers on the heart, since many antipsychotics can prolong the QT interval. Baseline ECG when feasible, with ongoing QTc monitoring during therapy, helps detect problematic changes early, especially if other QT-prolonging drugs or electrolyte disturbances are present. Regular checks for sedation level, movement disorders, and hydration/electrolyte status are also important, with dose adjustments or switching agents if adverse effects or significant QT prolongation occur.

More practice questions